Page 4 - Metastatic castration-naive and castration-sensitive prostate cancer: CUA/CUOG
P. 4
Methods
• MEDLINE and Embase were searched from January 2000 to August 2019
• An expert panel comprised of urologists, medical oncologists, and
radiation oncologists with significant experience managing mCNPC/mCSPC
was used to develop the recommendations
• Levels of evidence and grades of recommendation employ the ICUD/WHO
modified Oxford Center for Evidence-Based Medicine grading system
– Wherever Level 1 evidence is lacking, the guideline provides expert opinion
• The strength of each recommendation is represented by the words
STRONG or WEAK
ICUD: International Consultation on Urologic Diseases; mCNPC: metastatic castration-naive prostate cancer;
mCSPC: metastatic castration-sensitive prostate cancer; WHO: World Health Organization
